Order S E, Klein J L, Leichner P K
NCI Monogr. 1987(3):7-41.
Hepatocellular cancer, due to its size and location, allows tumor volume reconstruction and dosimetric determination when radiolabeled antibodies are administered during therapy. Factors identified in the treatment of this cancer may have general applicability for the radiolabeled antibody treatment of other malignancies. These factors include antibody preparations, labeling levels, and toxic effects. New findings regarding tumor volume saturation and altered tumor vascular permeability following radiation have important implications and should be investigated in other tumor systems. Another important development is the use of a new radiolabel, 90Y, in cyclic therapy, which is the sequential use of antibodies derived from different species. This therapy has increased the radiation dose to the tumor.
由于肝细胞癌的大小和位置，在治疗过程中给予放射性标记抗体时，可进行肿瘤体积重建和剂量测定。在这种癌症治疗中确定的因素可能对其他恶性肿瘤的放射性标记抗体治疗具有普遍适用性。这些因素包括抗体制剂、标记水平和毒性作用。关于辐射后肿瘤体积饱和和肿瘤血管通透性改变的新发现具有重要意义，应在其他肿瘤系统中进行研究。另一项重要进展是在循环治疗中使用新的放射性标记物钇-90，即依次使用来自不同物种的抗体。这种治疗增加了肿瘤的辐射剂量。
